Viking Therapeutics (NASDAQ:VKTX) reported quarterly earnings results on February 11, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-1.38, missing the consensus estimate of $-0.90 by $0.48 per share. Revenue came in at , missing the estimate of $10.0M.
Viking Therapeutics's stock moved following the earnings release. The stock currently trades at $30.49 with a market capitalization of $4.2B.